Kiniksa Pharmaceuticals International (KNSA) is back in focus after reporting fourth quarter and full year 2025 results, showing higher revenue and a shift to profitability that has drawn fresh attention from traders.
See our latest analysis for Kiniksa Pharmaceuticals International.
The earnings release on 24 February, followed by plans to present at the TD Cowen Health Care Conference and a recent ESOP related shelf filing, comes after a strong run, with a 90 day share price return of 10.44% and a 1 year total shareholder return of 116.36%. This is signalling momentum that traders are watching closely, despite a 1 day share price decline of 2.64% to US$46.02.
If Kiniksa’s recent move has you thinking about where growth and risk might show up next in healthcare, it could be worth scanning our curated list of 32 healthcare AI stocks as a starting point.
With Kiniksa now profitable, a 1-year total shareholder return above 100% and the stock still trading below the average analyst price target, the key question is whether there is still a buying opportunity or if the market is already pricing in future growth.
Most Popular Narrative: 17.6% Undervalued
With Kiniksa’s fair value in the most followed narrative sitting at about $55.88 versus a last close of $46.02, the gap between price and expectations is clear and sets up a punchy story about what drives that number.
The company's consistently high payer coverage/approval rates (>90%), strong therapy compliance, and robust commercial execution (e.g., AI-driven marketing and digital outreach) are cited as factors that could support scale efficiencies and improved net margins, contributing to operational leverage and profitability.
Want to see what sits behind that confidence in payer support and margin expansion? The narrative focuses on expectations related to revenue, earnings, and profit profile over time. The numbers behind those assumptions are where the real story starts.
Result: Fair Value of $55.88 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on Arcalyst staying ahead of future competitors and on pipeline assets delivering. Any stumble there could quickly challenge that 17.6% undervalued story.
Find out about the key risks to this Kiniksa Pharmaceuticals International narrative.
Another Way To Look At The Price
The fair value story presents Kiniksa as undervalued, but its P/E of 59.7x tells a very different story compared with US Biotechs at 21.6x and peers at 14.3x. Compared with a fair ratio of 24.1x, that is a wide gap, so the question is whether the market is being too optimistic.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If this mix of optimism and caution has you on the fence, it is worth looking through the details yourself and acting while the data is fresh. To see what the market currently views as the key positives, take a closer look at the 4 key rewards.
Ready For More Investment Ideas?
Do not stop your research with one company; broaden your watchlist using focused stock ideas so you can act quickly when something fits your plan.
- Spot potential value plays early by scanning our curated list of 47 high quality undervalued stocks that pair fundamentals with attractive pricing signals.
- Strengthen the quality of your portfolio by checking out the solid balance sheet and fundamentals stocks screener (41 results) that can help support resilience across different market conditions.
- Hunt for future contenders before they are widely followed by reviewing our screener containing 24 high quality undiscovered gems that combine smaller size with solid business metrics.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com